The Association between Coffee Consumption and Non-Alcoholic Fatty Liver Disease: Is there a Protective Role?
DOI:
https://doi.org/10.3889/oamjms.2023.10022Keywords:
non-alcoholic fatty liver disease, coffee, ultrasound, bright liver steatosis score, case control studyAbstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the main cause of chronic liver disease. Several studies have suggested a protective role of coffee in chronic liver disease, but their results remain controversial.
AIM: The purpose of the study was to investigate the association between coffee consumption and the prevalence and severity of NAFLD in a non-diabetic and non-alcoholic population.
METHODS: This study involved 157 participants. Cases were defined by the presence of steatosis on liver ultrasound, the severity of which was assessed by the Bright Liver Steatosis Score. Controls were defined by the absence of steatosis on liver ultrasound. All patients with cytolysis and/or cholestasis had an etiological investigation (serologic testing for Hepatitis B virus and hepatitis C virus infection, and autoimmune investigation). All participants underwent liver ultrasound, clinical assessment (blood pressure, waist circumference, and body mass index (BMI)), and biological assessment (Complete Blood Count, lipid profile test, liver function tests, and Fasting Blood Glucose [FBG]). Dietary assessment was conducted using a food frequency questionnaire, coffee consumption was dichotomized into present or absent and then categorized according to the number of cups consumed per day.
RESULTS: The study included 94 NAFLD and 63 controls, the two groups were comparable in demographic characteristics. The means of systolic blood pressure, BMI, waist circumference, Aspartate Transaminase, Alanine Transaminase (ALT), Gamma-Glutamyl transferase (GGT), alkaline phosphatase, and FBG were significantly higher in the NAFLD group. The study of the association between coffee consumption and NAFLD showed a significant decrease in the risk of its occurrence (Odds Ratios [OR] = 0.39) and its severity (OR = 0.32) in coffee consumers, mainly in those consuming 3 or more cups. In multivariate analysis, the following factors were associated with increased prevalence of NAFLD: Metabolic syndrome, high mean levels of alkaline phosphatase, GGT, ALT, FBG, BMI, and waist circumference. However, Green tea consumption was not associated with either prevalence or severity of NAFLD (OR = 1.02, p = 0.82).
CONCLUSION: Coffee consumption is inversely associated with the prevalence and severity of NAFLD. Further prospective studies are needed to establish a cause-effect relationship between coffee and NAFLD.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-9. https://doi.org/10.1016/j.jhep.2020.03.039 PMid:32278004 DOI: https://doi.org/10.1016/j.jhep.2020.07.045
Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease. BMJ. 2021;372:m4747. https://doi.org/10.1136/bmj.m4747 PMid:33461969 DOI: https://doi.org/10.1136/bmj.m4747
Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547-55. https://doi.org/10.1053/j.gastro.2014.11.039 PMid:25461851 DOI: https://doi.org/10.1053/j.gastro.2014.11.039
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57. https://doi.org/10.1002/hep.29367 PMid:28714183 DOI: https://doi.org/10.1002/hep.29367
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL–EASD– EASO Clinical Practice Guidelines for the management of the non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388- 402. https://doi.org/10.1016/j.jhep.2015.11.004 PMid:27062661 DOI: https://doi.org/10.1016/j.jhep.2015.11.004
Lavine JE. Effect of Vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents. JAMA. 2011;305(16):1659. https://doi.org/10.1001/jama.2011.520 PMid:21521847 DOI: https://doi.org/10.1001/jama.2011.520
Nordestgaard AT, Thomsen M, Nordestgaard BG. Coffee intake and risk of obesity, metabolic syndrome and type 2 diabetes: A Mendelian randomization study. Int J Epidemiol. 2015;44(2):551-65. https://doi.org/10.1093/ije/dyv083 PMid:26002927 DOI: https://doi.org/10.1093/ije/dyv083
Ebadi M, Ip S, Bhanji RA, Montano-Loza AJ. Effect of coffee consumption on non-alcoholic fatty liver disease incidence, prevalence and risk of significant liver fibrosis: Systematic review with meta-analysis of observational studies. Nutrients. 2021;13(9):3042. https://doi.org/10.3390/nu13093042 PMid:34578919 DOI: https://doi.org/10.3390/nu13093042
Mathiesen U, Franzen L, Åselius H, Resjö M, Jacobsson L, Foberg U, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis. 2002;34(7):516-22. https://doi.org/10.1016/s1590-8658(02)80111-6 PMid:12236486 DOI: https://doi.org/10.1016/S1590-8658(02)80111-6
Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome. Circulation. 2009;120(16):1640-5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644 PMid:19805654 DOI: https://doi.org/10.1161/CIRCULATIONAHA.109.192644
Catalano D, Martines GF, Tonzuso A, Pirri C, Trovato FM, Trovato GM. Protective role of coffee in non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2010;55(11):3200-6. https://doi.org/10.1007/s10620-010-1143-3 PMid:20165979 DOI: https://doi.org/10.1007/s10620-010-1143-3
Zelber-Sagi S, Salomone F, Webb M, Lotan R, Yeshua H, Halpern Z, et al. Coffee consumption and nonalcoholic fatty liver onset: A prospective study in the general population. Transl Res. 2015;165(3):428-36. https://doi.org/10.1016/j.trsl.2014.10.008 PMid:25468486 DOI: https://doi.org/10.1016/j.trsl.2014.10.008
Anty R, Marjoux S, Iannelli A, Patouraux S, Schneck A, Bonnafous S, et al. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol. 2012;57(5):1090-6. https://doi.org/10.1016/j.jhep.2012.07.014 PMid:22820478 DOI: https://doi.org/10.1016/j.jhep.2012.07.014
Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology. 2012;55(2):429-36. https://doi.org/10.1002/hep.24731 PMid:21987293 DOI: https://doi.org/10.1002/hep.24731
Bambha K, Wilson LA, Unalp A, Loomba R, Neuschwander-Tetri BA, Brunt EM, et al. Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int. 2014;34(8):1250-8. https://doi.org/10.1111/liv.12379 PMid:24267865 DOI: https://doi.org/10.1111/liv.12379
Veronese N, Notarnicola M, Cisternino A, Reddavide R, Inguaggiato R, Guerra V, et al. Coffee intake and liver steatosis: A population study in a Mediterranean Area. Nutrients. 2018;10(1):89. https://doi.org/10.3390/nu10010089 PMid:29342916 DOI: https://doi.org/10.3390/nu10010089
Alferink LJ, Fittipaldi J, Kiefte-de Jong JC, Taimr P, Hansen BE, Metselaar HJ, et al. Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: The Rotterdam study. J Hepatol. 2017;67(2):339-48. https://doi.org/10.1016/j.jhep.2017.03.013 PMid:28578837 DOI: https://doi.org/10.1016/j.jhep.2017.03.013
Arauz J, Zarco N, Segovia J, Shibayama M, Tsutsumi V, Muriel P. Caffeine prevents experimental liver fibrosis by blocking the expression of TGF-β. Eur J Gastroenterol Hepatol. 2014;26(2):164-73. https://doi.org/10.1097/MEG.0b013e3283644e26 PMid:23903851 DOI: https://doi.org/10.1097/MEG.0b013e3283644e26
Shim SG, Jun DW, Kim EK, Saeed WK, Lee KN, Lee HL, et al. Caffeine attenuates liver fibrosis via defective adhesion of hepatic stellate cells in cirrhotic model. J Gastroenterol Hepatol. 2013;28(12):1877-84. https://doi.org/10.1111/jgh.12317 PMid:23808892 DOI: https://doi.org/10.1111/jgh.12317
Furtado KS, Prado MG, Aguiar e Silva MA, Dias MC, Rivelli DP, Rodrigues MA, et al. Coffee and caffeine protect against liver injury induced by thioacetamide in male wistar rats. Basic Clin Pharmacol Toxicol. 2012;111(5):339-47. https://doi.org/10.1111/j.1742-7843.2012.00903.x PMid:22646289 DOI: https://doi.org/10.1111/j.1742-7843.2012.00903.x
Vitaglione P, Morisco F, Mazzone G, Amoruso DC, Ribecco MT, Romano A, et al. Coffee reduces liver damage in a rat model of steatohepatitis: The underlying mechanisms and the role of polyphenols and melanoidins. Hepatology. 2010;52(5):1652-61. https://doi.org/10.1002/hep.23902 PMid:21038411 DOI: https://doi.org/10.1002/hep.23902
Rodriguez de Sotillo DV, Hadley M, Sotillo JE. Insulin receptor exon 11+/− is expressed in Zucker (fa/fa) rats, and chlorogenic acid modifies their plasma insulin and liver protein and DNA. J Nutr Biochem. 2006;17(1):63-71. https://doi.org/10.1016/j.jnutbio.2005.06.004 PMid:16169204 DOI: https://doi.org/10.1016/j.jnutbio.2005.06.004
Xiao J, Ho CT, Liong EC, Nanji AA, Leung TM, Lau TY, et al. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways. Eur J Nutr. 2014;53(1):187-99. https://doi.org/10.1007/s00394-013-0516-8 PMid:23515587 DOI: https://doi.org/10.1007/s00394-013-0516-8
Mishra P, Younossi ZM. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol. 2007;102(12):2716-7. https://doi.org/10.1111/j.1572-0241.2007.01520.x PMid:18042105 DOI: https://doi.org/10.1111/j.1572-0241.2007.01520.x
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Anass Nadi, Zineb Oulammou, Meryem Maizi, Hanane Delsa, Fedoua Rouibaa (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
